Trial
NCT03744910
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
CSL Behring
Collaborators
ICON Clinical Research
Condition
Antibody-mediated Rejection
Intervention
Clazakizumab
Why stopped
Early stop for lack of efficacy/futility (at Interim analysis)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-23